Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T NetworkJakob Rudzki, Philipp Wohlfarth, Hildegard Greinix et al.|Blood|2022Cited by 1
Comparative analysis of ide-cel and cilta-cel in patients with Relapsed/Refractory multiple myeloma: A nationwide, retrospective, real-world analysis across AustriaIrene Straßl, Krauth Maria-Theresa, Alexander Nikoloudis et al.|Blood|2025Cited by 0
Impact of Disease Biology and Bridging Strategy on Outcomes After CAR-T Cell Therapy in Relapsed/Refractory Multiple MyelomaIrene Straßl, Maria‐Theresa Krauth, Alexander Nikoloudis et al.|Transplantation and Cellular Therapy|2026Cited by 0